Introduction

Knee osteoarthritis (OA) is a common and progressive condition that affects millions of people worldwide. One particular form, medial-compartment OA, affects the inner side of the knee and brings unique challenges. This area takes on extra stress during normal movement, causing cartilage wear and a bow-legged alignment known as varus deformity. These changes often bring pain, reduced walking distance, and difficulty standing comfortably, all of which can seriously impact quality of life.

As research deepens our understanding of medial-compartment knee OA, there is a growing need for treatments that focus specifically on this inner-knee region. Arthrosamid, an injectable hydrogel, is attracting attention as a modern option designed to provide lasting relief and support exactly where it’s needed. This represents an important step forward in personalised care for knee OA.

Understanding Medial-Compartment Knee Osteoarthritis

Medial-compartment knee osteoarthritis mainly affects the cartilage on the inner side of the knee joint. This cushioning layer gradually wears away, often worsened by varus alignment — a bow-legged posture that places additional pressure on this part of the knee. As that cartilage thins, the bones can start to rub together, causing pain and limiting how well the joint functions.

Studies show that “individuals with medial knee OA experience knee laxity and instability” (Lewek et al., 2005). To compensate, these patients “attempt to stabilise the knee with greater co-contraction of the medial muscle in response to laxity” (Lewek et al., 2005). Unfortunately, this increased muscle tightening can “contribute to higher joint compression and could exacerbate joint destruction,” potentially speeding up the joint’s deterioration (Lewek et al., 2005).

Patients with medial knee OA often suffer from inner-knee pain, stiffness after resting, and trouble walking or standing for long periods. These symptoms can seriously restrict mobility, making treatments that specifically target the inner knee vital.

Arthrosamid: How It Works and What Studies Show

Arthrosamid is an advanced treatment that involves injecting a biocompatible hydrogel directly into the knee joint. It’s designed to replace lost cushioning by adding durable shock absorption right where cartilage has worn away. The hydrogel remains stable within the joint space, helping restore smoother movement and potentially reducing pain while improving function.

Research affirms that “Arthrosamid® has been known to be safe and efficacious in knee osteoarthritis (OA) patients” (Gao et al., 2025a). However, the same study points out that “the literature surrounding which patients would incur the most benefit from Arthrosamid is limited,” emphasising the need for more research to understand who will benefit most (Gao et al., 2025a).

Another study observed that “PAAG provided improvement in knee OA symptoms over 24 months, in older, non-diabetic patients with lower KL grades” (Gao et al., 2025b). This suggests Arthrosamid can offer long-term pain relief and better mobility, particularly for carefully selected patients.

The Professional Approach: Professor Paul Lee and MSK Doctors

Professor Paul Lee is a highly respected expert specialising in cartilage science and orthopaedic surgery. He serves as a Regional Surgical Ambassador and advisor to the Royal College of Surgeons of Edinburgh. With extensive experience in musculoskeletal medicine and rehabilitation, he is well placed to guide patients considering new treatments like Arthrosamid.

MSK Doctors deliver a patient-centred service focusing on musculoskeletal health. Their thorough assessments and tailored treatment plans ensure every patient receives expert advice and support throughout their journey. Such professional care is invaluable when exploring cutting-edge therapies for complex conditions like medial-compartment knee OA.

Who Might Benefit Most? Important Considerations

Arthrosamid could be especially helpful for patients with significant cartilage wear limited to the medial compartment, a varus leg alignment, or those whose symptoms have not sufficiently improved with traditional treatments like physiotherapy or pain relief medications. Yet, as research highlights, “we aim to identify which patient factors would allow Arthrosamid to provide the most clinical benefit” (Gao et al., 2025a). This underlines the importance of a personalised approach.

Moreover, researchers remind us that “current literature on the best patient selection for PAAG is limited,” and that further studies are needed to “validate efficacy, refine patient selection, and evaluate long-term impact” (Gao et al., 2025b). Therefore, a careful, expert assessment is essential before considering this treatment.

Patients are encouraged to discuss realistic outcomes and the need for follow-up monitoring with their healthcare provider. While risks of Arthrosamid are generally low, potential side effects such as minor injection site reactions should be openly discussed.

Conclusion

To summarise, Arthrosamid offers a focused and innovative treatment for medial-compartment knee osteoarthritis by restoring cushioning and reducing symptoms in the inner knee. When applied under expert care from clinicians like Professor Paul Lee and the MSK Doctors team, it has the potential to improve comfort and mobility. Their professional guidance ensures treatment is tailored to individual patient needs, supporting better outcomes.

For personalised medical advice, please consult a qualified healthcare professional.

References

• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., & Lee, P. Y. (2025a). THE IMPACT OF PATIENT FACTORS ON THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE OF ARTHROSAMID POLYACRYLAMIDE HYDROGEL INJECTION FOR KNEE OSTEOARTHRITIS: A COHORT STUDY. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2025.02.648
• Gao, H. C. K., Akhtar, M., Creedon, C., Nar, Ö. O., Verma, T., & Lee, P. Y. F. (2025b). Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. Journal of Clinical Orthopaedics and Trauma. https://doi.org/10.1016/j.jcot.2025.103136
• Lewek, M. D., Ramsey, D. K., Snyder‐Mackler, L., & Rudolph, K. S. (2005). Knee stabilization in patients with medial compartment knee osteoarthritis. Arthritis & Rheumatism, 52(9), 2845–2853. https://doi.org/10.1002/art.21237